Bleeding in advanced CKD patients on antithrombotic medication – A critical appraisal

[1]  Jonathan H Seltzer,et al.  Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints , 2019, European heart journal.

[2]  M. Banach,et al.  The quest for equilibrium: exploring the thin red line between bleeding and ischaemic risks in the management of acute coronary syndromes in chronic kidney disease patients , 2017, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  Deepak L. Bhatt,et al.  Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease , 2017, The New England journal of medicine.

[4]  P. Rothwell,et al.  Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study , 2017, The Lancet.

[5]  M. Sánchez-Niño,et al.  Translational science in chronic kidney disease. , 2017, Clinical science.

[6]  F. Zannad,et al.  Cardiovascular Outcome Trials in Patients With Advanced Kidney Disease: Time for Action. , 2017, Circulation.

[7]  M. Neuss,et al.  Predictors of thrombus formation after percutaneous left atrial appendage closure using the WATCHMAN device , 2017, Heart and Vessels.

[8]  C. Ronco,et al.  Prospective, Randomized, Multicenter, Controlled Trial (TRIATHRON 1) on a New Antithrombogenic Hydrophilic Dialysis Membrane , 2017, The International journal of artificial organs.

[9]  S. Genovesi,et al.  Recent Advances in Stroke Prevention in Patients with Atrial Fibrillation and End-Stage Renal Disease , 2017, Cardiorenal Medicine.

[10]  Ran Liu,et al.  Comparison of the performance of the CRUSADE, ACUITY-HORIZONS, and ACTION bleeding scores in ACS patients undergoing PCI: insights from a cohort of 4939 patients in China , 2017, Journal of geriatric cardiology : JGC.

[11]  L. Polonski,et al.  Renal function on admission affects both treatment strategy and long-term outcomes of patients with myocardial infarction (from the Polish Registry of Acute Coronary Syndromes). , 2017, Kardiologia polska.

[12]  M. Turakhia,et al.  Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease , 2016, Heart.

[13]  G. Lip,et al.  Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. , 2016, The New England journal of medicine.

[14]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[15]  Neel M. Butala,et al.  Use of Chronic Oral Anticoagulation and Associated Outcomes Among Patients Undergoing Percutaneous Coronary Intervention , 2016, Journal of the American Heart Association.

[16]  M. Sarnak,et al.  Pericarditis and Pericardial Effusions in End‐Stage Renal Disease , 2016, Seminars in dialysis.

[17]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European heart journal.

[18]  S. Yusuf,et al.  The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study , 2016, The Lancet.

[19]  P. Schulman,et al.  Stroke, Major Bleeding, and Mortality Outcomes in Warfarin Users With Atrial Fibrillation and Chronic Kidney Disease: A Meta-Analysis of Observational Studies. , 2016, Chest.

[20]  B. Meier,et al.  Impact of chronic kidney disease on left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation. , 2016, International journal of cardiology.

[21]  Bingcheng Zhao,et al.  Efficacy and safety of antithrombotic regimens after coronary intervention in patients on oral anticoagulation: Traditional and Bayesian meta-analysis of clinical trials. , 2016, International journal of cardiology.

[22]  T. Hohlfeld,et al.  Antiplatelet effects of aspirin in chronic kidney disease patients , 2016, Journal of thrombosis and haemostasis : JTH.

[23]  Jeroen J. Bax,et al.  2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). , 2011, European heart journal.

[24]  P. Noseworthy,et al.  Meta-Analysis of Renal Function on the Safety and Efficacy of Novel Oral Anticoagulants for Atrial Fibrillation. , 2016, The American journal of cardiology.

[25]  A. Hoes,et al.  2016 European Guidelines on cardiovascular disease prevention in clinical practice. , 2016, Revista espanola de cardiologia.

[26]  J. Messenger,et al.  Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study. , 2015, JACC. Cardiovascular interventions.

[27]  K. Alexander,et al.  Accuracy of bleeding scores for patients presenting with myocardial infarction: a meta-analysis of 9 studies and 13 759 patients , 2015, Postepy w kardiologii interwencyjnej = Advances in interventional cardiology.

[28]  R. Peters,et al.  Influence of chronic kidney disease on anticoagulation levels and bleeding after primary percutaneous coronary intervention in patients treated with unfractionated heparin , 2015, Journal of Thrombosis and Thrombolysis.

[29]  Y. Yang,et al.  Proton pump inhibitors in prevention of low-dose aspirin-associated upper gastrointestinal injuries. , 2015, World journal of gastroenterology.

[30]  S. Booth,et al.  Influence of kidney function on risk of supratherapeutic international normalized ratio-related hemorrhage in warfarin users: a prospective cohort study. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[31]  T. Potpara,et al.  Left atrial appendage closure-indications, techniques, and outcomes: results of the European Heart Rhythm Association Survey. , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[32]  A. Santoro,et al.  Warfarin use, mortality, bleeding and stroke in haemodialysis patients with atrial fibrillation. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[33]  M. Tonelli,et al.  The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study , 2015, BMJ : British Medical Journal.

[34]  E. Edelman,et al.  Dabigatran and Rivaroxaban Use in Atrial Fibrillation Patients on Hemodialysis , 2015, Circulation.

[35]  C. Franssen,et al.  Results of the HepZero study comparing heparin-grafted membrane and standard care show that heparin-grafted dialyzer is safe and easy to use for heparin-free dialysis. , 2014, Kidney international.

[36]  Saibal Kar,et al.  Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. , 2014, JAMA.

[37]  A. Ariza-Solé,et al.  Efficacy of bleeding risk scores in elderly patients with acute coronary syndromes. , 2014, Revista espanola de cardiologia.

[38]  F. Piscione,et al.  Transradial versus Transfemoral Approach in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome. A Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials , 2014, PloS one.

[39]  Tsung-Hsien Lin,et al.  Additive effect of in-hospital TIMI bleeding and chronic kidney disease on 1-year cardiovascular events in patients with acute coronary syndrome , 2014, Heart and Vessels.

[40]  A. Ariza-Solé,et al.  CRUSADE bleeding risk score validation for ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention. , 2013, Thrombosis research.

[41]  G. Stone,et al.  Transradial versus transfemoral percutaneous coronary intervention in acute coronary syndromes: re-evaluation of the current body of evidence. , 2013, JACC. Cardiovascular interventions.

[42]  L. Køber,et al.  Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. , 2013, Journal of the American College of Cardiology.

[43]  P. Rossignol,et al.  Rationale and design of the HepZero study: a prospective, multicenter, international, open, randomized, controlled clinical study with parallel groups comparing heparin-free dialysis with heparin-coated dialysis membrane (Evodial) versus standard care: study protocol for a randomized controlled tria , 2013, Trials.

[44]  A. Kastrati,et al.  Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. , 2013, Journal of the American College of Cardiology.

[45]  G. Wander,et al.  Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation 2.3-year follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection In Patients With Atrial Fibrillation) trial. , 2013 .

[46]  Tom Adriaenssens,et al.  Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial , 2013, The Lancet.

[47]  A. Castro‐Beiras,et al.  Comparison of the performance of the CRUSADE, ACUITY-HORIZONS, and ACTION bleeding risk scores in STEMI undergoing primary PCI: insights from a cohort of 1391 patients , 2013, European heart journal. Acute cardiovascular care.

[48]  S. Yusuf,et al.  Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial , 2013, Circulation.

[49]  M. Jeong,et al.  Impact of Clopidogrel loading dose in patients with chronic kidney disease undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. , 2012, The American journal of cardiology.

[50]  Gerhard Hindricks,et al.  2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[51]  Jeroen J. Bax,et al.  2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. , 2012, European heart journal.

[52]  D. Atar,et al.  ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation , 2013 .

[53]  S. Raposeiras-Roubín,et al.  Comparing the predictive validity of three contemporary bleeding risk scores in acute coronary syndrome , 2012, European heart journal. Acute cardiovascular care.

[54]  A. Webster,et al.  Effects of Antiplatelet Therapy on Mortality and Cardiovascular and Bleeding Outcomes in Persons With Chronic Kidney Disease , 2012, Annals of Internal Medicine.

[55]  Helmut Baumgartner,et al.  ESC / EACTS Guidelines on myocardial revascularization , 2014 .

[56]  G. Stone,et al.  Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. , 2011, JACC. Cardiovascular interventions.

[57]  D. Singer,et al.  A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. , 2011, Journal of the American College of Cardiology.

[58]  Marco Valgimigli,et al.  Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.

[59]  Gregory Y H Lip,et al.  Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. , 2011, Journal of the American College of Cardiology.

[60]  Gregory Y H Lip,et al.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. , 2010, Chest.

[61]  S. Pocock,et al.  A risk score to predict bleeding in patients with acute coronary syndromes. , 2010, Journal of the American College of Cardiology.

[62]  K. Alexander,et al.  Use of Evidence-Based Therapies in Short-Term Outcomes of ST-Segment Elevation Myocardial Infarction and Non–ST-Segment Elevation Myocardial Infarction in Patients With Chronic Kidney Disease: A Report From the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network R , 2010, Circulation.

[63]  S. Werns.  Impact of Chronic Kidney Disease on Major Bleeding Complications and Mortality in Patients With Indication for Oral Anticoagulation Undergoing Coronary Stenting , 2010 .

[64]  B. Faurie.  [Transradial approach and kidney disease]. , 2009, Annales de cardiologie et d'angeiologie.

[65]  Marc Cohen,et al.  Balancing myocardial ischemic and bleeding risks in patients with non-ST-segment elevation myocardial infarction. , 2009, The American journal of cardiology.

[66]  Salim Yusuf,et al.  Effect of clopidogrel added to aspirin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[67]  Sunil V. Rao,et al.  Baseline Risk of Major Bleeding in Non–ST-Segment–Elevation Myocardial Infarction: The CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Bleeding Score , 2009, Circulation.

[68]  G. Boysen,et al.  European Guidelines on Cardiovascular Disease Prevention , 2009, International journal of stroke : official journal of the International Stroke Society.

[69]  B. Faurie.  [Transradial approach and kidney disease]. , 2009, Annales de cardiologie et d'angeiologie.

[70]  David L. Brown,et al.  The impact of advanced chronic kidney disease on in‐hospital mortality following percutaneous coronary intervention for acute myocardial infarction , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[71]  R. Holden,et al.  Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[72]  D. Malhotra,et al.  HEMATOLOGY: ISSUES IN THE DIALYSIS PATIENT: Platelet Dysfunction and End‐Stage Renal Disease , 2006, Seminars in dialysis.

[73]  Xu Zhimi.  Association of hemoglobin levels with clinical outcomes in acute coronary syndrome , 2006 .

[74]  K. Alexander,et al.  Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. , 2005, JAMA.

[75]  R. Califf,et al.  Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. , 2005, The American journal of cardiology.

[76]  R. Giugliano,et al.  Association of Hemoglobin Levels With Clinical Outcomes in Acute Coronary Syndromes , 2005, Circulation.

[77]  C. Wanner,et al.  Section V. Chronic intermittent haemodialysis and prevention of clotting in the extracorporal system. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.